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Abstract 
Most of the kidney transplanted patients develop arterial hypertension after renal transplantation. Together with 
very well-known and usual risk factors, post-transplant hypertension contributes to the whole cardiovascular 
morbidity and mortality in the kidney transplant population. The reasons of post-transplant hypertension are 
factors related to donors and recipients, immunosuppressive therapy like Calcineurin Inhibitors (CNI) and surgery 
procedures (stenosis and kinking of the renal artery and ureteral obstruction). According to Eighth National 
Committee (JNC 8) recommendations, blood pressure > 140/90 mmHg is considered as hypertension. The usual 
antihypertensive drugs used for the control of hypertension are Calcium channel blockers (CCB), Angiotensin-
converting enzyme (ACE) inhibitors, Angiotensin –II receptor blockers (ARB), B- blockers and diuretics. Follow the 
KDIGO guidelines the target blood pressure < 140/90 mmHg for patients without proteinuria and < 125/75 mmHg 
in patients with proteinuria is recommended. Better control of post-transplant hypertension improves the long-term 
graft and patient’s survival. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Post-transplant cardiovascular disease 
Kidney transplantation is the optimal 
treatment of patients with ESRD who would otherwise 
require dialysis. Despite the fact that kidney 
transplantation reduces the risk of both, 
cardiovascular morbidity and mortality remain a 
leading cause of death with functioning graft among 
kidney transplant recipients (KTR) [1], [2], [3], [4] 
Among the traditional and non-traditional risk factors, 
post-transplant hypertension (PTxH) remains one of 
the major contributors to the post-transplant 
cardiovascular morbidity (PTCVM) and mortality and 
the most common causes of chronic graft dysfunction 
and kidney transplant failure [5], [6], [7], [8]. 
Cardiovascular pathology is responsible for 
approximately 40% of deaths among KTR [9]. The 
annual risk of fatal and non-fatal cardiovascular 
events in KTR is 3-5% which is 50-fold higher than in 
the general population. Both, classical and non-
classical cardiovascular factors equally contribute to 
the increased incidence of PTCVM [10], [11], [12]. 
 
Hypertension and Post-Transplant 
Hypertension 
According to 8-the report of Joint National 
Committee on Prevention, Detection, Evaluation and 
Treatment of High Blood Pressure (JNC 8) the new 
blood pressure classification was introduced bearing 
in mind the target organ damage and the presence of 
other factors of comorbidity like Chronic Kidney 
Disease (CKD), Diabetes, BMI, Hyperlipidemia etc. 
Thus, Hypertension is defined if office BP is ≥ 140/90 
and ambulatory BP ≥ 130/90 in normal persons under 
the age of 60. The prevalence of PTxH among kidney 
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recipients is between 55-90% [13], [14]. Significant 
contributions to the clinical outcome of hypertensive 
KTR are age, BMI, time after the surgery, gender, 
presence of chronic allograft nephropathy, cellular and 
antibody-mediated rejection episodes, use of 
immunosuppressant, etc.  
Regarding hypertension in CKD and 
transplant patients, KDIGO recommendations are 
more strict: The BP should be kept below or equal of 
130/85 and 125/75 if the patients are proteinuric [15], 
[16]. The introduction and acceptance of ambulatory 
blood pressure (ABP) control in the follow up of 
hypertension in general population as well as in KTR 
enables more detailed classification of hypertension 
and therefore a new patient stratification. In KTR both, 
office and ambulatory BP control should be performed 
in every day clinical practice. Out of the hypertension 
classification according to the JNC 8, recently different 
types of hypertension were clinically introduced as: 
Masked Hypertension (MH), White Coat Hypertension 
(WCH), Sustained Hypertension (SH), Isolated 
Nocturnal Hypertension (INH), Isolated Diurnal 
Hypertension (IDH), Awake and Asleep hypertension, 
all with `confirmed clinical significance [17], [18], [19], 
[20] The most investigated types of hypertension 
among kidney transplant recipients and CKD patients 
are WCH and MH. WCH is defined as well-controlled 
home hypertension but poorly controlled clinic 
hypertension. MH is the reverse phenomenon, poorly 
controlled BP at home but normal in the clinic.  
The prevalence of MH among KTR is 
between 23 and 58% with a confirmed harmful effect 
on graft and patients survival. WCH with a percentage 
of 4-20% is less important, but still require awareness 
[20], [21], [22]. The appearance of resistant 
hypertension (7% of PTxH) is also a confirmed entity 
which should be treated successfully with carefully 
chosen antihypertensive drugs [23], [24], [25]. All 
types of hypertension defined by ABP monitoring are 
largely investigated in renal transplant recipients and 
are parts of the efforts to control PTxH on a 
recommended level according to KDIGO criteria. 
Table 1 presents a different classification of 
Hypertension which is also used in KTR.  
TABLE 1: Definition, types and classification of hypertension 
Types Values 
CBP – clinical blood pressure Average BP ≥ 140/90 
ABP – Ambulatory blood pressure Average BP ≥ 130/90 
Awake ABP BP ≥ 135/85 
Sleep ABP BP ≥ 120/70 
Normotension CBP and ABP within the normal range 
Masked Hypertension CBP – within normotensive range 
ABP – within hypertensive range 
White coat Hypertension CBP – within hypertensive range 
ABP – within normotensive range 
Sustained Hypertension  CBP – within hypertensive range 
ABP – within normotensive range 
Nighttime Hypertension (Nocturnal) Awake ABP – within normotensive range 
Sleep ABP –within hypertensive 
Daytime Hypertension (Diurnal) Awake ABP – within hypertensive range 
Sleep ABP – within normotensive range 
All-day Hypertension Awake ABP – within hypertensive range 
Sleep ABP – within hypertensive range 
CBP – office control of BP; AMB – 24 h – ambulatory BP control. 
 
Pathogenesis of post-transplant 
hypertension 
 
The pathogenesis of hypertension during the 
post-transplant period is multifactorial which include 
traditional and non-traditional risk factors. Some of 
them are related to transplant surgery, underlying 
kidney disease, use of immunosuppression, chronic or 
acute graft rejections. The majority of these factors 
are reversible, and some are preventable. They are 
presented in Table 2. 
TABLE 2: Causes of Post-Transplant Hypertension 
Factors Examples 
Immunosuppression Cyclosporine 
Tacrolimus 
Glucocorticoid 
Graft disease Delayed graft function 
Chronic allograft nephropathy 
De novo and recurrent glomerular disease 
Acute rejection 
Recipient factors Underlying kidney disease 
Essential hypertension 
Native kidney presence 
Excessive weight gain 
Secondary Hyperparathyroidism 
Donor factors Preexisting donor hypertension 
Advanced donor age 
Subarachnoidal haemorrhage 
Use of right kidney 
Female gender 
Surgery Transplant renal artery stenosis 
Use of right kidney 
Cold and warm ischemia time 
Renal artery and vein anastomosis time 
 
Regarding the mechanism of PTxH it seems 
that both, volume load and vasoconstriction are 
present. In the case of renal artery stenosis and CNI 
dependent hypertension, the vasoconstriction 
dominates due to the increase of renin-angiotensin 
system, up-regulation of endothelin-1 and reduction of 
the bioavailability of nitric oxide. Both cyclosporine 
and tacrolimus may cause a salt-sensitive form of 
hypertension with the consecutive fluid overload [26], 
[27], [28].  
Among donor dependent risk factors are 
already well-confirmed age, history of hypertension, 
underlying disease (diabetes) vascular disease and 
genetic predisposition. The use of steroids facilitates 
sodium and volume retention and contributes to 
insulin resistance and diabetes.  
The positive experience of renal denervation 
of native kidneys in renal transplant recipients, even in 
several cases, emphases the possible role of 
sympathetic overactivity [29], [30]. The appearance of 
renal transplant artery stenosis put for sure RA 
system in the game which could be solved with the 
appropriate therapeutic procedure. In the cases of 
recurrent or de-novo glomerulonephritis, classical 
mechanisms of renal hypertension are involved [31]. 
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Long term consequences 
 
Increased cardiovascular morbidity and 
mortality 
Like in general population many studies 
confirmed a PTxH as a strong risk factor for ischemic 
heart disease, congestive heart failure, coronary 
artery disease, increased arterial stiffness and stroke. 
The most clinically significant consequence of 
hypertension is left ventricular hypertrophy, left atrial 
enlargement and diastolic dysfunction which are 
responsible for a variety of cardiovascular events after 
kidney transplantation. Some authors find a strong 
correlation between left ventricular hypertrophy and 
post-transplant isolated nocturnal hypertension while 
24-hour ABP hypertension and altered Night-Day BP 
profile are independently associated with Carotid 
Intima/Media thickness [32], [33]. 
 
Chronic Graft Dysfunction 
Together with rejection, PTxH is one of the 
major factors which is responsible for reduced long-
term graft and patients survival. A single centre study 
on long-term kidney transplant survival rate, KTR with 
diastolic BP of 89-99 mm Hg had statistically 
decreased GFR compared to recipients with lower 
blood pressure. Also, recipients with lower blood 
pressure in the first year have better graft survival. 
The study of Mange et al. demonstrated the increased 
risk of graft failure for every 10 mm Hg in SBP and 10 
mm Hg in diastolic BP [34]. Higher blood pressure 
correlates with greater rates of progression of 
decreased renal function.  
Chronic allograft nephropathy, renamed by 
Banff classification with interstitial fibrosis and tubular 
atrophy (IF-TA), is associated with gradual 
deterioration in graft function, relevant proteinuria and 
new or worsening hypertension in the absence of any 
other worsening factors. Non-HLA antibody-mediated 
rejection, with an antibody targeting angiotensin II 
type receptors, develops hypertension secondary to 
vascular rejection. According to the Collaborative 
Transplant Study PTxH is an independent risk factor 
for chronic allograft nephropathy and graft failure [35]. 
Increasing systolic BP was associated with decreased 
graft survival at any level of diastolic pressure.  
Regarding the association with host 
alloimmune response and acute and chronic rejection, 
post-transplant hypertension has been confirmed 
among the rejection of free kidney transplant 
recipients. However, it could be not excluded that PTH 
has a deleterious effect of graft small vessels with an 
increasing of immunogenicity of impaired graft tissue. 
In addition, some experimental studies confirmed that 
hypertension increases expression of growth factors 
and MHC II in chronic allograft nephropathy. PTxH is 
strongly associated with chronic allograft nephropathy 
and vice-versa and presents a significant non-
immunological risk factor for late graft failure. Altered 
day-night BP profile, reverse dipper pattern are also 
associated with early inflammation and constitutes an 
independent predictor of graft failure [36], [37], [38], 
[39], [40]. 
 
 
Treatment 
 
Lifestyle 
The usual recommendations of the 
Hypertension Associations worldwide may also be 
applied to kidney transplant recipients. Slightly 
reduction of salt intake, 30-60 min of moderate daily 
physical or aerobic activity, maintenance of body 
mass index between 18-25 kg/m2 and keeping the 
waist circumference under 102 for men and <88 for 
women. Light dietetic measures could also be 
recommended as a low-fat diet, moderate alcohol 
consumption and more vegetables and fruit in 
everyday nutrition [27]. 
 
Treatment target and pharmacological 
management 
Bearing in mind all the consequences of non-
controlled BP in KTR, achievement of target BP level 
is strongly recommended. The pharmacological 
treatment should start when office BP is more than 
140/90 or ABP more than 130/80 as well as in any 
case of isolated nocturnal, masked and sustained 
hypertension or altered day-night time BP profile. The 
start should be with thiazide diuretics with the addition 
of Calcium Channel Blockers (CCB), Angiotensin-II 
Receptor Blockers (ARB) and Angiotensin-II 
Converting Enzyme (ACE) inhibitors according to the 
KDIGO and JNC 8 recommendations [13], [15]. But 
the regulation and reaching of target BP level are far 
of an easy task. An average analyses of BP in kidney 
transplant recipients confirm that despite the whole 
spectrum of antihypertensives and careful BP 
measurements, the majority of the patients are still 
uncontrolled. Whenever we should start our 
pharmacological approach to the PTxH, hypertensive 
effects of CNI (especially Cyclosporine A) has to be 
taken into consideration. The use of other 
immunosuppressive protocols including mTOR 
inhibitors or Belatacept instead of CNI may provide 
better control and beneficial effects on long term graft 
and patients survival [27]. 
 
Invasive procedures 
In patients with proven transplant renal artery 
stenosis, Percutaneous transluminal angioplasty 
(PTA) and surgery could be applied if the degree of a 
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stenotic lesion is more than 80%. However, it should 
be careful in decision because of polar infarcts, 
haematoma, intimal flaps, thrombosis and 
anastomotic re-stenosis [29], [30]. 
Renal denervation of the native kidneys is an 
interesting and probably promising therapeutic 
procedure which can be effective in some individual 
cases. A few reports confirmed a beneficial effect of 
this procedure, but it is still far of any definitive 
conclusion. Interestingly the effect was on nocturnal, 
and ABP was some of the non-dipper patients 
became dipper [31]. 
In the recent report from Dallas (USA), 
Lerman et al. performed laparoscopic bilateral 
nephrectomy in 5 cases of resistant hypertension in 
kidney and pancreas transplant recipients. Mean 
arterial pressure improved in the next six months after 
the surgery and renal function remained stable. 
Despite the beneficial results of this small report, there 
is no sufficient data to recommend this aggressive 
procedure. The future controlled studies should 
confirm the justification of surgical approach as a 
therapeutic measure [41].  
 
 
Conclusion 
 
The high prevalence of arterial hypertension 
in KTR contributes to chronic graft damage and 
significantly decreased graft and long-term patient 
survival. Despite the evidence of the adverse effects 
of hypertension, BP control has been poor despite the 
use of different combinations of antihypertensive 
drugs. Adequate diagnosis methods should be 
permanently implemented using classical office and 
home BP readings. Twenty-four hour ABPM allows 
very valuable information on circadian rhythm and 
nocturnal blood pressure. PTH remains a very 
important issue in clinical follow up of kidney 
transplant recipients. 
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